CHICAGO--(BUSINESS WIRE)--Genentech, Inc. (NYSE:DNA) today announced that a Roche-sponsored, randomized placebo-controlled Phase III clinical study of Avastin® (bevacizumab) in combination with interferon alfa-2a therapy increased the median time patients with first-line metastatic renal cell carcinoma (mRCC) lived without their cancer growing or spreading as defined by progression-free survival (PFS). Patients receiving Avastin plus interferon alfa-2a therapy experienced a 59 percent improvement in PFS (based on a hazard ratio of 0.63) compared to those receiving interferon alfa-2a therapy alone.
